Nanologica AB (publ)

Stockholm Stock Exchange NICA.ST

Nanologica AB (publ) Total Non-Current Liabilities for the year ending December 31, 2023: USD 6.66 M

Nanologica AB (publ) Total Non-Current Liabilities is USD 6.66 M for the year ending December 31, 2023, a 2.78% change year over year. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.

Nanologica AB (publ) Total Non-Current Liabilities for the year ending December 31, 2022 was USD 6.48 M, a 82.62% change year over year.
Nanologica AB (publ) Total Non-Current Liabilities for the year ending December 31, 2021 was USD 3.55 M, a -17.88% change year over year.
Nanologica AB (publ) Total Non-Current Liabilities for the year ending December 31, 2020 was USD 4.32 M, a 69.52% change year over year.
Nanologica AB (publ) Total Non-Current Liabilities for the year ending December 31, 2019 was USD 2.55 M, a 964.62% change year over year.

Key data

Date	Total Non-Current Liabilities	Shareholders' Equity	Other Liabilities	Total Liabilities

Stockholm Stock Exchange: NICA.ST

Nanologica AB (publ)

CEO	Mr. Andreas Bhagwani
IPO Date	Oct. 30, 2015
Location	Sweden
Headquarters	Forskargatan 20G
Employees	16
Sector	Health Care
Industries Biotechnology Chemicals & Advanced Materials Petrochemicals Pharmaceuticals

Description

Nanologica AB (publ), a nanotechnology company, develops nanoporous silica for applications in the life science industry. The company offers nanoporous silica particles for drug development and chromatography separation. It provides NLAB Silica, a technology platform for drug delivery; NLAB Spiro, an inhalation platform for pulmonary drug delivery; SVEA (U)HPLC analytical columns; and preparative chromatography. Nanologica AB (publ) was founded in 2004 and is based in Södertälje, Sweden.

Key trends

Past 5 years